Skip to main content
Top
Published in: Substance Abuse Treatment, Prevention, and Policy 1/2020

01-12-2020 | Opioids | Commentary

PTSD and opioid use: implications for intervention and policy

Authors: Lucia Dahlby, Thomas Kerr

Published in: Substance Abuse Treatment, Prevention, and Policy | Issue 1/2020

Login to get access

Abstract

Background

North America remains in the midst of an escalating opioid overdose epidemic, largely driven by the influx of synthetic opioids such a fentanyl and related analogues. High rates of mental illness among substance-using populations have been well documented; in particular, opioid-using individuals suffer from high rates of PTSD. Despite the devastating disease burden of both PTSD and OUD, especially within the context of the current opioid overdose epidemic, treatment options and outcomes remain suboptimal.

Main body

Comorbid PTSD-OUD is often complex and inextricably intertwined, thereby impeding effective diagnosis, assessment and early intervention. Best outcomes occur when treatment addresses both comorbidities simultaneously, known as parallel or integrative approaches. Despite these findings, affected individuals often do not receive adequate or equitable access to healthcare. The WHO recommends that public spending for both mental and physical aspects of healthcare be equitable to the burden of disease. Despite these recommendations mental healthcare services remain chronically underfunded in Canada. The Mental Health Parity Act is a call for the Canadian government to implement equitable public spending on all aspects of healthcare. Furthermore, prohibitory legislative practices serve to marginalize substance-using populations thereby increasing the likelihood of exposure to traumatic violence and other associated harms.

Conclusion

Efforts are now needed to address regulatory drug-use frameworks and public healthcare policies that perpetuate these inequalities. Alternative regulatory frameworks for drugs and mental health parity should be implemented and evaluated in an effort to reduce violence, trauma and ultimately opioid-related overdose deaths.
Literature
2.
go back to reference Roberts NP, Roberts PA, Jones N, Bisson JI. Psychological interventions for post-traumatic stress disorder and comorbid substance use disorder: a systematic review and meta-analysis. Clin Psychol Rev. 2015;38:25–38.CrossRef Roberts NP, Roberts PA, Jones N, Bisson JI. Psychological interventions for post-traumatic stress disorder and comorbid substance use disorder: a systematic review and meta-analysis. Clin Psychol Rev. 2015;38:25–38.CrossRef
3.
go back to reference Fareed A, Eilender P, Haber M, Bremner J, Whitfield N, Drexler K. Comorbid posttraumatic stress disorder and opiate addiction: a literature review. J Addict Dis. 2013;32(2):168–79.CrossRef Fareed A, Eilender P, Haber M, Bremner J, Whitfield N, Drexler K. Comorbid posttraumatic stress disorder and opiate addiction: a literature review. J Addict Dis. 2013;32(2):168–79.CrossRef
4.
go back to reference Ecker AH, Hundt N. Posttraumatic stress disorder in opioid agonist therapy: A review. Psychol Trauma. 2018;10(6):636.CrossRef Ecker AH, Hundt N. Posttraumatic stress disorder in opioid agonist therapy: A review. Psychol Trauma. 2018;10(6):636.CrossRef
5.
go back to reference Gielen N, Havermans R, Tekelenburg M, Jansen A. Prevalence of post-traumatic stress disorder among patients with substance use disorder: it is higher than clinicians think it is. Eur J Psychotraumatol. 2012;3(1):17734.CrossRef Gielen N, Havermans R, Tekelenburg M, Jansen A. Prevalence of post-traumatic stress disorder among patients with substance use disorder: it is higher than clinicians think it is. Eur J Psychotraumatol. 2012;3(1):17734.CrossRef
6.
go back to reference Schwartz RP, Gryczynski J, O’grady KE, Sharfstein JM, Warren G, Olsen Y, Mitchell SG, Jaffe JH. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. Am J Public Health. 2013;103(5):917–22.CrossRef Schwartz RP, Gryczynski J, O’grady KE, Sharfstein JM, Warren G, Olsen Y, Mitchell SG, Jaffe JH. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. Am J Public Health. 2013;103(5):917–22.CrossRef
7.
go back to reference Abuse S, (US), Mental Health Services Administration, (US), Office of the Surgeon General, NCBI Bookshelf. Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs and Health. US Department of Health and Human Services; 2016. Abuse S, (US), Mental Health Services Administration, (US), Office of the Surgeon General, NCBI Bookshelf. Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs and Health. US Department of Health and Human Services; 2016.
9.
go back to reference Vigo DV, Kestel D, Pendakur K, Thornicroft G, Atun R. Disease burden and government spending on mental, neurological, and substance use disorders, and self-harm: cross-sectional, ecological study of health system response in the Americas. Lancet Public Health. 2019;4(2):e89–96.CrossRef Vigo DV, Kestel D, Pendakur K, Thornicroft G, Atun R. Disease burden and government spending on mental, neurological, and substance use disorders, and self-harm: cross-sectional, ecological study of health system response in the Americas. Lancet Public Health. 2019;4(2):e89–96.CrossRef
10.
go back to reference Hughes CE, Stevens A. What can we learn from the Portuguese decriminalization of illicit drugs? Bri J Criminol. 2010;50(6):999–1022.CrossRef Hughes CE, Stevens A. What can we learn from the Portuguese decriminalization of illicit drugs? Bri J Criminol. 2010;50(6):999–1022.CrossRef
Metadata
Title
PTSD and opioid use: implications for intervention and policy
Authors
Lucia Dahlby
Thomas Kerr
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Substance Abuse Treatment, Prevention, and Policy / Issue 1/2020
Electronic ISSN: 1747-597X
DOI
https://doi.org/10.1186/s13011-020-00264-8

Other articles of this Issue 1/2020

Substance Abuse Treatment, Prevention, and Policy 1/2020 Go to the issue